Pfizer cited many reasons for ending sales of hemophilia B gene therapy Beqvez, including a lack of patient and doctor interest. The company no longer plans to develop AAV gene therapies.
Less than two months after Pfizer opted to give up its rights to late-stage Sangamo Therapeutics-partnered hemophilia A gene therapy...
UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.
The Belgian drugmaker is boosting its biologics capacity over the pond.
Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.
Plus deals involving BioAge/JiKang, Sanyou/Medicovestor, AriBio/Acino, Intragrand/Transpire, Kaken/Twocells, Sumitomo/Novo Nordisk, NIBEC/Undisclosed, Formosa/Adalvo, Drug Farm/Amoytop, Lupin/SteinCares and Lupin/Honeywell.
Gilead’s Kite division presented Phase I data for its next-generation CAR-T therapy KITE-363 in patients with B-cell lymphomas.
But the French major is still keen on early-stage M&A.
Buy boosts the French major's immunology pipeline.
